Skip to main content
. 2021 Sep 8;13:689939. doi: 10.3389/fnagi.2021.689939

FIGURE 3.

FIGURE 3

Distribution of serum levels of pituitary adenylate-cyclase activating polypeptide (PACAP) and vasoactive intestinal peptide (VIP) by Hoehn–Yahr (H-Y) stage. (A) There were no significant differences in the distribution of serum PACAP levels by H-Y stage in Parkinson’s disease (PD) patients (P > 0.05). (B) There were no significant differences in the distribution of serum VIP levels by H-Y stage in PD patients (P > 0.05).